88Q Stock Overview
Engages in the research, development, manufacturing, and commercialization of synthetic DNA and RNA products, and targeted non-viral vector solutions in the United States, Europe, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
4basebio PLC Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£15.60 |
| 52 Week High | UK£21.20 |
| 52 Week Low | UK£6.25 |
| Beta | 1.13 |
| 11 Month Change | -3.11% |
| 3 Month Change | -7.69% |
| 1 Year Change | 143.75% |
| 33 Year Change | 103.92% |
| 5 Year Change | n/a |
| Change since IPO | 92.00% |
Recent News & Updates
Recent updates
Shareholder Returns
| 88Q | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -0.6% | 0.8% | -1.3% |
| 1Y | 143.8% | -17.5% | 7.4% |
Return vs Industry: 88Q exceeded the German Biotechs industry which returned -17.5% over the past year.
Return vs Market: 88Q exceeded the German Market which returned 7.4% over the past year.
Price Volatility
| 88Q volatility | |
|---|---|
| 88Q Average Weekly Movement | 2.0% |
| Biotechs Industry Average Movement | 6.4% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.8% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 88Q has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: 88Q's weekly volatility (2%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | 101 | Heikki Lanckriet | www.4basebio.com |
4basebio PLC engages in the research, development, manufacturing, and commercialization of synthetic DNA and RNA products, and targeted non-viral vector solutions in the United States, Europe, and internationally. The company offers AVV and Lentivirus manufacturing services for use in gene therapies and vaccines. It also offers access to its targeted non-viral delivery platform, Hermes.
4basebio PLC Fundamentals Summary
| 88Q fundamental statistics | |
|---|---|
| Market cap | €200.01m |
| Earnings (TTM) | -€11.82m |
| Revenue (TTM) | €716.07k |
279.3x
P/S Ratio-16.9x
P/E RatioIs 88Q overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 88Q income statement (TTM) | |
|---|---|
| Revenue | UK£596.00k |
| Cost of Revenue | UK£181.00k |
| Gross Profit | UK£415.00k |
| Other Expenses | UK£10.25m |
| Earnings | -UK£9.84m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.77 |
| Gross Margin | 69.63% |
| Net Profit Margin | -1,650.67% |
| Debt/Equity Ratio | -296.9% |
How did 88Q perform over the long term?
See historical performance and comparison